For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
Thymosin beta-4 sulfoxide (Tβ4-SO) is a naturally occurring oxidation derivative of the parent peptide thymosin beta-4, formed when the methionine-6 residue of Tβ4 is oxidized by hydrogen peroxide (H2O2) at sites of inflammation. It is a distinct compound from its parent: oxidation attenuates Tβ4's intracellular G-actin sequestering function but substantially enhances its extracellular anti-inflammatory and immune-resolution signaling. TB4-SO is not the same compound as TB-500 (the actin-binding fragment Ac-LKKTETQ used in the peptide community) nor the same as Tβ4 itself. Evidence is limited to two key publications: the 1999 Young et al. Nature Medicine paper establishing glucocorticoid-induced monocyte production and in vitro/in vivo anti-inflammatory effects, and the 2013 Evans et al. Nature Communications paper demonstrating cardiac wound healing promotion in zebrafish, mouse, and human cell culture. No human clinical trials have been conducted.
Three distinct compounds are routinely confused in the peptide community and require explicit clarification before reading this profile:
1. Thymosin beta-4 (Tβ4): the full 43-amino acid parent peptide, also known as TB-500 in veterinary and grey market use (though technically TB-500 refers to the fragment). Tβ4 is WADA-prohibited. Profiled separately in this database (profile #4, TB-500).
2. TB-500 / Ac-LKKTETQ: a synthetic 7-amino acid fragment corresponding to amino acids 17 to 23 of Tβ4, representing the actin-binding motif. This is the compound sold as 'TB-500' and the compound sold by Integrative Peptides as 'TB4-FRAG' (at 250 mcg per capsule). This is NOT TB4-SO.
3. Thymosin beta-4 sulfoxide (Tβ4-SO): this profile. An oxidation product formed by H2O2 acting on the methionine-6 residue of Tβ4. It is formed naturally at sites of inflammation by the respiratory burst of neutrophils and macrophages, and by monocytes in the presence of glucocorticoids. It is a chemically and functionally distinct compound from both Tβ4 and TB-500.
The biological story of Tβ4-SO is mechanistically elegant: the same H2O2 burst that attracts neutrophils and macrophages to a wound converts extracellular Tβ4 into Tβ4-SO, which then signals those immune cells to disperse -- acting as the resolution signal that prevents chronic inflammation. In this model, Tβ4-SO is not an alternative to Tβ4; it is the subsequent step in a two-phase inflammatory regulation sequence. The parent Tβ4 is involved in promoting wound repair and new vessel growth; the sulfoxide derivative Tβ4-SO is the downstream signal for resolution of the inflammatory phase.
WADA note: Tβ4 itself is explicitly named on the WADA 2026 Prohibited List under S2. Tβ4-SO is a direct chemical derivative of Tβ4 differing by a single oxygen atom. Athletes should assume Tβ4-SO is prohibited under the same category as a related substance; no separate WADA ruling on Tβ4-SO specifically has been published.
Evidence state: Tβ4-SO has two key papers. Everything else in this profile is mechanistic context or background from the parent Tβ4 literature. The evidence base for Tβ4-SO as an exogenous therapeutic is sparse -- there are no animal dosing studies using administered Tβ4-SO, only mechanistic studies examining its endogenous production and effects. Tβ4-SO is not commercially available in any consistent form, and community use of this compound specifically (as opposed to TB-500 or Tβ4) appears minimal.
Thymosin beta-4 (Tβ4) is a ubiquitous 43-amino acid actin-sequestering peptide with well-documented roles in wound healing, angiogenesis, and inflammation modulation (profiled separately). The discovery that Tβ4 could be oxidized to a functionally distinct derivative emerged from research at the University of Glasgow in the late 1990s, led by J.D. Young's group studying anti-inflammatory signals generated by immune cells in the presence of glucocorticoids.
Young et al. (1999) identified thymosin beta-4 sulfoxide in the supernatants of monocytes cultured with glucocorticoids. The sulfoxide form had previously been known to exist (as a natural consequence of methionine oxidation in any peptide), but its biological activity had not been characterized. Young's key finding was that glucocorticoids -- the most potent endogenous anti-inflammatory hormones -- induced monocytes to secrete Tβ4-SO, and that this sulfoxide form had distinct and potent anti-inflammatory properties not shared by native Tβ4. This suggested that part of glucocorticoids' anti-inflammatory mechanism might be mediated through Tβ4-SO production.
The second foundational paper came from the Riley group at Oxford (Evans et al., 2013). Using zebrafish as a model organism with optically transparent larvae allowing real-time imaging of immune cell behavior, the group demonstrated that H2O2 released from a wound triggers Tβ4-SO formation, and that Tβ4-SO acts as the downstream 'resolution signal' that disperses inflammatory cells from the wound site. This placed Tβ4-SO within the mechanistic framework of wound inflammation resolution: H2O2 first attracts immune cells (the acute phase) and then drives Tβ4-SO production to disperse them (the resolution phase). The mouse cardiac injury data and human ex vivo cell culture data in the same paper extended the finding across species.
The community product landscape adds further confusion. Integrative Peptides markets 'TB4-FRAG' as a product containing the 'Thymosin Beta 4 Active Fragment,' which refers to the actin-binding heptapeptide (amino acids 17 to 23, Ac-LKKTETQ) -- not the sulfoxide. Searches for 'TB4-SO' in the peptide community sometimes encounter this product, but they are unrelated compounds with different mechanisms.
The mechanism of TB4-SO is best understood as a two-phase model of inflammatory regulation operating downstream of the initial H2O2 wound signal.
Phase 1, initiation: at the site of tissue injury, hydrogen peroxide (H2O2) is rapidly produced by damaged tissue and the respiratory burst of recruited neutrophils and macrophages. H2O2 serves as an initial chemotactic signal that attracts inflammatory cells to the wound -- it promotes inflammation. Tβ4 is simultaneously released at the wound site by platelets and local cells.
Phase 2, Tβ4-SO generation: H2O2 oxidizes the methionine-6 residue of extracellular Tβ4, converting it to Tβ4-SO. This chemical transformation is not damage; it is a regulatory switch. The oxidation specifically changes the peptide's biological activity: actin-sequestering capacity (Tβ4's intracellular role) is attenuated by methionine oxidation, while extracellular anti-inflammatory signaling is enhanced. Glucocorticoids separately induce monocytes to generate and secrete Tβ4-SO, linking the steroid anti-inflammatory pathway to this resolution mechanism.
Phase 3, resolution signaling: Tβ4-SO acts on neutrophils and macrophages to: inhibit neutrophil chemotaxis (reduces migration toward inflammatory signals); promote dispersive locomotion (scatters immune cells away from the wound focus rather than accumulating them); lower adhesion of neutrophils and monocytes to vascular endothelial cells (reducing further immune cell extravasation); inhibit macrophage response to fMLP (formyl-methionyl-leucyl-phenylalanine), a major bacterial chemoattractant; inhibit interferon-gamma (IFN-gamma) production in T cell and monocyte co-cultures; and stimulate monocyte dispersal and cell death via increased superoxide production.
The cardiac wound healing application: in the zebrafish cardiac injury model (Evans et al. 2013), Tβ4-SO was detected in wounded tissue within 1 hour at elevated levels (5-fold increase). Tβ4-SO-soaked beads implanted at zebrafish wound sites significantly reduced macrophage accumulation within a 500 micrometer radius at 3 and 6 hours post-wounding. In the mouse cardiac model, Tβ4-SO promoted wound healing and reduced scarring after cardiac injury -- the downstream consequence being reduced fibrosis and less pathological cardiac remodeling.
The distinction from parent Tβ4 is mechanistically important: Tβ4 promotes wound repair, angiogenesis, stem cell mobilization, and early inflammatory modulation. Tβ4-SO is specifically the resolution signal that clears the inflammatory phase. These are complementary, sequential functions -- not redundant ones. Exogenous administration of Tβ4-SO would theoretically replicate only the resolution-phase effects, without the full regenerative repertoire of the parent peptide.
In zebrafish larval tail fin wounding, Tβ4-SO levels increased approximately 5-fold from 2.0% plus or minus 1.4% SEM to 10.4% plus or minus 1.96% SEM within 1 hour post-wounding (n=100 tail fins per treatment, p less than or equal to 0.01). Pre-treatment with the H2O2 inhibitor DPI reduced this increase to 3-fold (6.4% plus or minus 0.8% SEM, p less than or equal to 0.05 vs. vehicle controls), establishing H2O2 as the upstream trigger for Tβ4-SO formation in live tissue.
Tβ4-SO-soaked beads implanted in zebrafish larvae significantly reduced macrophage (MPO-/L-plastin+) accumulation within a 500 micrometer radius at 3 and 6 hours post-wounding compared to vehicle-soaked bead controls (n=5 fish per treatment, p less than or equal to 0.05). Neutrophil accumulation was not significantly reduced by Tβ4-SO at these timepoints, suggesting the resolution effect is specific to macrophages at the timepoints studied.
In a zebrafish cardiac laser injury model, a reduced leukocytic response (L-plastin staining) was seen in Tβ4-SO-treated fish within 500 micrometers of the focal cardiac injury point at 3 hours post-injury. In the mouse cardiac injury model, Tβ4-SO promoted wound healing and reduced scarring compared to controls -- directly relevant to the problem of non-functional scar formation and cardiac remodeling after myocardial infarction.
In human ex vivo co-cultures of CD4+ T cells and CD14+ monocytes: Tβ4-SO significantly decreased IFN-gamma levels (n=4 co-cultures per treatment); Tβ4-SO significantly reduced monocyte adherence in both single monocyte cultures and T cell co-cultures in the presence of IFN-gamma (n=3 cultures per treatment); vital dye staining demonstrated Tβ4-SO significantly increased monocyte cell death, further increased by IFN-gamma (n=3 per treatment). These ex vivo findings establish that the biological effects are not species-specific artifacts -- human immune cells respond to Tβ4-SO.
The Evans 2013 Nature Communications study is the primary evidence for TB4-SO's cardiac and wound healing properties and is a well-designed mechanistic study across three biological systems (zebrafish, mouse, human ex vivo). It establishes the mechanistic framework -- H2O2 triggers Tβ4-SO formation, which then acts as a resolution signal for inflammatory cell dispersal. The mouse cardiac scarring reduction is the most therapeutically relevant preclinical finding. No in vivo human intervention data exists for Tβ4-SO in any indication.
Young et al. (1999) is the foundational Tβ4-SO paper. The group was investigating which factors in glucocorticoid-conditioned monocyte supernatants produced the distinctive dispersive locomotion of neutrophils. They identified Tβ4-SO as the active component: monocytes cultured in the presence of glucocorticoids generate and secrete Tβ4-SO, which inhibits neutrophil chemotaxis, promotes neutrophil dispersive locomotion (rather than directed migration), lowers neutrophil adhesion to endothelial cells, and inhibits neutrophil chemotactic response to fMLP.
The critical in vivo result: Tβ4-SO, but NOT native Tβ4, was a potent inhibitor of carrageenan-induced edema in the mouse paw when injected directly. Native Tβ4 had no significant anti-inflammatory effect in this carrageenan model at comparable doses. This result is the central piece of evidence that Tβ4-SO is not simply a degraded form of Tβ4 but a functionally superior anti-inflammatory molecule in the extracellular compartment.
The mechanistic interpretation: oxidation of methionine-6 converts Tβ4 from an intracellular actin-sequestering molecule (whose primary function is cytoskeletal regulation) into an extracellular anti-inflammatory signaling molecule. The paper proposed that part of glucocorticoids' powerful anti-inflammatory mechanism may be mediated through induction of Tβ4-SO production by monocytes -- an indirect downstream pathway for steroid anti-inflammatory action.
The Young 1999 Nature Medicine study is a strong mechanistic paper establishing the carrageenan in vivo result as the most compelling preclinical anti-inflammatory evidence for Tβ4-SO. The finding that the sulfoxide form (but not native Tβ4) inhibits carrageenan edema is the clearest functional distinction between the two compounds. The glucocorticoid induction mechanism is a novel and interesting finding that has not been followed up with human clinical data.
The parent peptide Tβ4 has an established and favorable safety profile from human trials: Phase 1 at doses from 42 to 1260 mg for 14 days showed no toxicities; Phase 2 trials for venous stasis ulcers, pressure ulcers, and epidermolysis bullosa found accelerated wound repair with no adverse events. Phase 2 dry eye and neurotrophic keratopathy trials showed positive clinical effects lasting beyond the treatment period. This clinical safety record belongs to Tβ4 -- NOT to Tβ4-SO.
The two compounds should not be conflated for clinical purposes. Tβ4 acts primarily through: intracellular G-actin sequestration (regulating cytoskeletal dynamics); promoting cell migration and stem/progenitor cell mobilization; angiogenesis via VEGF-dependent and independent pathways; and broad anti-inflammatory effects including NF-kB inhibition and cytokine modulation. Tβ4-SO specifically: does NOT sequester actin (oxidation attenuates this); inhibits neutrophil chemotaxis and disperses macrophages; inhibits IFN-gamma; and promotes monocyte dispersal and cell death. These are complementary but mechanistically distinct activities.
TB-500 (the heptapeptide fragment Ac-LKKTETQ) is a third distinct entity: it retains the actin-binding activity of Tβ4 and promotes cell migration and wound healing through that mechanism, but lacks the N-terminal region responsible for Tβ4's anti-inflammatory and anti-fibrotic effects. A 2024 study reported that TB-500 itself may not enhance wound healing activity, and that its active metabolite Ac-LKKTE may be responsible for whatever activity is observed in that fragment. TB-500 is WADA-prohibited (S0, non-approved substances).
Practitioners and readers should note: the safety data for Tβ4 cannot be applied to Tβ4-SO; the wound healing data for Tβ4 is mechanistically different from Tβ4-SO's anti-inflammatory resolution mechanism; and the community use of 'TB-500' products as 'TB4-SO' is a misidentification of compounds.
This use case establishes the critical distinctions between three related but non-identical compounds. The clinical trial data for Tβ4 (parent) is not transferable to Tβ4-SO without separate human studies. The commercial TB-500 fragment is different from both. Anyone evaluating Tβ4-SO should understand that essentially all clinical human data in the TB4 space belongs to the full-length parent peptide, which has different mechanisms and different indications from the sulfoxide form.
The mechanistic rationale for Tβ4-SO as an anti-inflammatory therapeutic is grounded in the problem of chronic inflammation following acute tissue injury. In the adult mammalian heart, the failure to resolve inflammation after myocardial infarction leads to persistent macrophage accumulation, ongoing fibroblast activation, and progressive scar formation and fibrosis -- the mechanism underlying post-MI heart failure and cardiac remodeling. Tβ4-SO, as the endogenous resolution signal, could theoretically be administered exogenously to accelerate or augment this resolution phase.
More broadly, failure of inflammation resolution (rather than uncontrolled inflammation initiation) is increasingly recognized as a driver of many chronic inflammatory diseases. The field of resolution pharmacology seeks agents that actively promote resolution rather than simply suppressing inflammation. Tβ4-SO falls conceptually within this framework -- it is not immunosuppressive but rather a physiological signal for orderly immune cell withdrawal from completed wound sites.
The glucocorticoid connection also has therapeutic implications: if part of how steroids reduce inflammation is by inducing Tβ4-SO production from monocytes, then Tβ4-SO or its analogs could potentially achieve some steroid-like anti-inflammatory effects without the adverse effects of systemic glucocorticoid use (HPA axis suppression, glucose dysregulation, bone density loss, etc.). This remains entirely theoretical.
What has not been done: no animal dosing study of exogenously administered Tβ4-SO has been published; the 1999 carrageenan study used local injection, not a systemic therapeutic model; no pharmacokinetic data exists; no dose-response relationship has been established in any species; no Phase 1 safety study exists. The Evans 2013 paper positions Tβ4-SO as a 'putative target' -- appropriately hedged language that the evidence base supports.
The therapeutic rationale for Tβ4-SO as a resolution pharmacology agent is mechanistically sound and addresses a real unmet need (preventing post-MI fibrosis, resolving chronic inflammation). But the pathway from mechanism to therapy has not been traversed at all -- there are no dosing studies, no pharmacokinetic data, no safety studies in animals or humans, and no clinical development program. The theoretical framework is promising; the practical development work remains entirely undone.
Tβ4-SO has no validated human dosing. It is not the same compound as TB-500 (Ac-LKKTETQ), TB4-FRAG (the Integrative Peptides oral product), or full-length Tβ4. No IND has been filed for Tβ4-SO. WADA status: treat as prohibited (Tβ4 derivative). The compound is available from peptide research suppliers as a research chemical, but with no human dosing guidance from any published clinical source. The in vitro effective concentration of 100 ng/mL in the Evans 2013 study cannot be converted to a human dose without pharmacokinetic characterization. The parent Tβ4 clinical trial data (42 to 1260 mg, 14 days, safe in Phase 1) belongs to the parent compound and cannot be used for Tβ4-SO dosing extrapolation given the different pharmacological profile. Any community use of a product labeled as TB4-SO should be approached with awareness that: there is no validated dose; there is no safety data; and standard peptide quality control concerns (purity, stability of the oxidized methionine form) apply.
TB4-SO is a derivative of thymosin beta-4, which is profiled separately as TB-500 (profile #4, covering the actin-binding fragment that is also marketed as TB-500). The three Tβ4-related compounds in the biohacking space -- full-length Tβ4, TB-500 (Ac-LKKTETQ fragment), and Tβ4-SO -- have distinct mechanisms and distinct evidence bases. Only the full-length Tβ4 has human clinical trial data. TB4-SO's anti-inflammatory resolution mechanism places it conceptually near BPC-157 (profile #1), which also modulates inflammatory resolution and wound healing through distinct pathways. SS-31 (profile #3) addresses inflammation at the mitochondrial level through a completely different mechanism. In the resolution pharmacology space, Ac-SDKP -- the N-terminal tetrapeptide cleavage product of Tβ4 with documented anti-fibrotic effects -- is another Tβ4 derivative mechanistically adjacent to TB4-SO; Ac-SDKP is not profiled separately in this database.
No human safety data for exogenous Tβ4-SO exists. No animal dosing studies have been published for Tβ4-SO administered as an exogenous therapeutic. The safety profile is entirely unknown from an intervention standpoint.
The parent Tβ4 has a well-characterized safety profile from clinical trials: Phase 1 trials using synthetic Tβ4 at doses from 42 to 1260 mg for 14 days showed no toxicities or serious adverse events. RegeneRx's Phase 2 clinical trials for dermal wounds, venous ulcers, and corneal applications found Tβ4 to be safe and well tolerated. These findings apply to the full-length parent peptide and cannot be directly extrapolated to the sulfoxide form, which has different receptor interactions and signaling properties.
A theoretical concern unique to Tβ4-SO (not shared by Tβ4) relates to its monocyte-dispersal and cell death-promoting activity. In the context of normal wound resolution, inducing monocyte dispersal and a degree of monocyte cell death is beneficial -- it clears the inflammatory phase and prevents chronic inflammation. However, exogenous administration of Tβ4-SO in contexts of infection, immunosuppression, or existing immune compromise could theoretically impair the immune response to pathogens by prematurely dispersing the inflammatory cells needed for pathogen clearance. This is a theoretical concern that has not been studied.
Cancer and angiogenesis: the parent Tβ4 raises concerns about supporting tumor angiogenesis and cell migration in pre-existing cancers. Tβ4-SO's attenuated actin-sequestering activity and different extracellular signaling profile mean this concern does not translate directly. Whether Tβ4-SO's anti-inflammatory and resolution signaling has pro-tumor or anti-tumor effects in any cancer context is entirely unstudied.
The endogenous context: Tβ4-SO is produced naturally in humans at every site of inflammation. There is no published report of pathological excess of endogenous Tβ4-SO. The compound is apparently rapidly turned over or further modified in the local inflammatory environment. Whether exogenous administration would produce systemic levels that differ meaningfully from endogenous production patterns is unknown.
Thymosin beta-4 sulfoxide occupies a peculiar position in peptide biology: it is mechanistically fascinating, biologically important as an endogenous signal, and essentially unstudied as a therapeutic candidate. Two publications -- Young 1999 in Nature Medicine and Evans 2013 in Nature Communications -- establish the foundational biology. Together they describe a coherent two-phase wound inflammatory regulation system where H2O2 first drives immune cell infiltration and then drives Tβ4-SO formation to resolve it. The cardiac application is particularly compelling: post-MI inflammation resolution is an active area of unmet clinical need, and Tβ4-SO's macrophage-dispersal activity directly addresses the mechanism of non-functional scar formation.
But the gap between these findings and any human application remains absolute. There are no published animal dosing studies for exogenous Tβ4-SO. There are no pharmacokinetic data. There is no safety characterization. There is no Phase 1 study. The field has generated an elegant mechanistic case and then... not followed through. The most likely reason is the challenge of obtaining and stabilizing the sulfoxide form (methionine oxidation is readily reversed by cellular reducing agents), combined with the generally underfunded state of resolution pharmacology relative to pro-inflammatory pathway inhibition.
The nomenclature confusion in the peptide community -- where 'TB4-FRAG,' 'TB-500,' 'Tβ4,' and 'TB4-SO' are sometimes used interchangeably -- means that whatever anecdotal reports exist for community use of 'TB4-SO' products likely reflect use of the actin-binding fragment or the parent peptide, not the sulfoxide form specifically. Genuine exogenous Tβ4-SO use in humans is probably negligible given the compound's relative obscurity and lack of commercial availability as a defined product.
Practitioners and readers: TB4-SO is a research compound. It is not the same as TB-500, TB4-FRAG, or the parent Tβ4. It has no dosing guidance, no safety data, and no human efficacy data. Its WADA status as a Tβ4 derivative should be assumed prohibited. Its interest lies in understanding how inflammation resolves -- not in any current therapeutic application.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use